MITF, the Janus transcription factor of melanoma

Future Oncology

Volumn 9, Issue 2, 2013, Pages 235-244

  Koludrovic, Dana ^a   Davidson, Irwin ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

catenin; BRAF; BRN2; GLI2; SUMO; TGF

Indexed keywords

BETA CATENIN; CYCLIC AMP; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR SOX10; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

BINDING SITE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE REGULATORY NETWORK; GENE SILENCING; GENE TARGETING; HUMAN; INTRACELLULAR SPACE; MELANOCYTE; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN PIGMENTATION; SUMOYLATION; TUMOR GROWTH; WNT SIGNALING PATHWAY;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MUTATION; SIGNAL TRANSDUCTION; SUMOYLATION;

EID: 84874076499     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.177     Document Type: Review

References (92)

1. Miller AJ, Mihm MC Jr. Melanoma. N. Engl. J. Med. 355(1), 51-65 (2006).
2. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21(1), 27-38 (2008).
3. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 23(1), 27-40 (2010).
4. Hoek KS, Eichhoff OM, Schlegel NC et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68(3), 650-656 (2008).
5. Widmer DS, Cheng PF, Eichhoff OM et al. Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res. 25(3), 343-353 (2012).
6. Hou L, Pavan WJ. Transcriptional and signaling regulation in neural crest stem cell-derived melanocyte development: do all roads lead to MITF? Cell Res. 18(12), 1163-1176 (2008).
7. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12(9), 406-414 (2006).
8. Garraway LA, Weir BA, Zhao X et al. "Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harb. Symp. Quant. Biol. 70, 25-34 (2005).
9. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 23(6), 746-759 (2010).
10. Giuliano S, Ohanna M, Ballotti R, Bertolotto C. Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res. 24(2), 295-308 (2011).
11. Strub T, Giuliano S, Ye T et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 30(20), 2319-2332 (2011).
12. Steingrimsson E, Copeland NG, Jenkins NA. Melanocytes and the microphthalmia transcription factor network. Annu. Rev. Genet. 38, 365-411 (2004).
13. Hodgkinson CA, Moore KJ, Nakayama A et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74(2), 395-404 (1993).
14. Oboki K, Morii E, Kataoka TR, Jippo T, Kitamura Y. Isoforms of mi transcription factor preferentially expressed in cultured mast cells of mice. Biochem. Biophys. Res. Commun. 290(4), 1250-1254 (2002).
15. Takeda K, Yasumoto K, Kawaguchi N et al. MITF-D, a newly identified isoform, expressed in the retinal pigment epithelium and monocyte-lineage cells affected by MITF mutations. Biochim. Biophys. Acta 1574(1), 15-23 (2002).
16. Takemoto CM, Yoon YJ, Fisher DE. The identification and functional characterization of a novel mast cell isoform of the microphthalmia-associated transcription factor. J. Biol. Chem. 277(33), 30244-30252 (2002).
17. Bertolotto C, Abbe P, Hemesath TJ et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J. Cell Biol. 142(3), 827-835 (1998).
18. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002).
19. Wellbrock C, Ogilvie L, Hedley D et al. V599EBRAF is an oncogene in melanocytes. Cancer Res. 64(7), 2338-2342 (2004).
20. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65(6), 2412-2421 (2005).
21. Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) BRaf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res. 67(12), 5814-5820 (2007).
22. Sharma A, Tran MA, Liang S et al. Targeting mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase in the mutant (V600E) BRaf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 66(16), 8200-8209 (2006).
23. Dhomen N, Reis-Filho JS, da Rocha Dias S et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15(4), 294-303 (2009).
24. Zhao Y, Zhang Y, Yang Z, Li A, Dong J. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem. Biophys. Res. Commun. 370(3), 509-513 (2008).
25. Dankort D, Curley DP, Cartlidge RA et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41(5), 544-552 (2009).
26. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to cKit signalling in melanocytes. Nature 391(6664), 298-301 (1998).
27. Wu M, Hemesath TJ, Takemoto CM et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14(3), 301-312 (2000).
28. Wellbrock C, Marais R. Elevated expression of MITF counteracts BRAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 170(5), 703-708 (2005).
29. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 3(7), e2734 (2008).
30. Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR. The Brn2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. 24(7), 2923-2931 (2004).
31. Goodall J, Carreira S, Denat L et al. Brn2 represses microphthalmia- associated transcription factor expression and marks a distinct subpopulation of microphthalmiaassociated transcription factor-negative melanoma cells. Cancer Res. 68(19), 7788-7794 (2008).
32. Pinner S, Jordan P, Sharrock K et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 69(20), 7969-7977 (2009).
33. Thurber AE, Douglas G, Sturm EC et al. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30(27), 3036-3048 (2011).
34. Kobi D, Steunou AL, Dembele D et al. Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene. Pigment Cell Melanoma Res. 23(3), 404-418 (2010).
35. Boyle GM, Woods SL, Bonazzi VF et al. Melanoma cell invasiveness is regulated by miR211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 24(3), 525-537 (2011).
36. Berlin I, Denat L, Steunou AL et al. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation. Mol. Cell. Biol. 32(7), 1237-1247 (2012).
37. Willert K, Nusse R. Beta-catenin: A key mediator of Wnt signaling. Curr. Opin. Genet. Dev. 8(1), 95-102 (1998).
38. Goodall J, Martinozzi S, Dexter TJ et al. Brn2 expression controls melanoma proliferation and is directly regulated by betacatenin. Mol. Cell. Biol. 24(7), 2915-2922 (2004).
39. Yasumoto K, Takeda K, Saito H, Watanabe K, Takahashi K, Shibahara S. Microphthalmia-associated transcription factor interacts with LEF1, a mediator of Wnt signaling. EMBO J. 21(11), 2703-2714 (2002).
40. Schepsky A, Bruser K, Gunnarsson GJ et al. The microphthalmia-associated transcription factor MITF interacts with beta-catenin to determine target gene expression. Mol. Cell. Biol. 26(23), 8914-8927 (2006).
41. Delmas V, Beermann F, Martinozzi S et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with NRas in melanoma development. Genes Dev. 21(22), 2923-2935 (2007).
42. Boye K, Nesland JM, Sandstad B, Maelandsmo GM, Flatmark K. Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur. J. Cancer 46(16), 2919-2925 (2010).
43. Liu L, Zhu XD, Wang WQ et al. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin. Cancer Res. 16(10), 2740-2750 (2010).
44. Chien AJ, Moore EC, Lonsdorf AS et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl Acad. Sci. USA 106(4), 1193-1198 (2009).
45. Arozarena I, Bischof H, Gilby D, Belloni B, Dummer R, Wellbrock C. In melanoma, beta-catenin is a suppressor of invasion. Oncogene 30(45), 4531-4543 (2011).
46. Gallagher SJ, Rambow F, Kumasaka M et al. Beta-catenin inhibits melanocyte migration but induces melanoma metastasis. Oncogene, doi: 10.1038/onc.2012.229 (2012) (Epub ahead of print).
47. Kim J, Lo L, Dormand E, Anderson DJ. SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. Neuron 38(1), 17-31 (2003).
48. Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene 22(20), 3024-3034 (2003).
49. Potterf SB, Mollaaghababa R, Hou L et al. Analysis of SOX10 function in neural crest-derived melanocyte development: SOX10dependent transcriptional control of dopachrome tautomerase. Dev. Biol. 237(2), 245-257 (2001).
50. Hou L, Arnheiter H, Pavan WJ. Interspecies difference in the regulation of melanocyte development by SOX10 and MITF. Proc. Natl Acad. Sci. USA 103(24), 9081-9085 (2006).
51. Lang D, Lu MM, Huang L et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433(7028), 884-887 (2005).
52. Epstein DJ, Vekemans M, Gros P. Splotch (Sp2H), a mutation affecting development of the mouse neural tube, shows a deletion within the paired homeodomain of Pax3. Cell 67(4), 767-774 (1991).
53. Opdecamp K, Kos L, Arnheiter H, Pavan WJ. Endothelin signalling in the development of neural crest-derived melanocytes. Biochem. Cell Biol. 76(6), 1093-1099 (1998).
54. Bohm M, Moellmann G, Cheng E et al. Identification of p90RSK as the probable CREBSer133 kinase in human melanocytes. Cell Growth Differ. 6(3), 291-302 (1995).
55. Sato-Jin K, Nishimura EK, Akasaka E et al. Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. FASEB J. 22(4), 1155-1168 (2008).
56. Goding CR. MITF from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 14(14), 1712-1728 (2000).
57. Yamaguchi Y, Hearing VJ. Physiological factors that regulate skin pigmentation. Biofactors 35(2), 193-199 (2009).
58. Hoek KS, Schlegel NC, Brafford P et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19(4), 290-302 (2006).
59. Dennler S, Andre J, Verrecchia F, Mauviel A. Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation. J. Biol. Chem. 284(46), 31523-31531 (2009).
60. Alexaki VI, Javelaud D, Van Kempen LC et al. GLI2-mediated melanoma invasion and metastasis. J. Natl Cancer Inst. 102(15), 1148-1159 (2010).
61. Javelaud D, Alexaki VI, Pierrat MJ et al. GLI2 and MMITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Pigment Cell Melanoma Res. 24(5), 932-943 (2011).
62. Pierrat MJ, Marsaud V, Mauviel A, Javelaud D. Expression of microphthalmiaassociated transcription factor (MITF), which is critical for melanoma progression, is inhibited by both transcription factor GLI2 and transforming growth factor-beta. J. Biol. Chem. 287(22), 17996-18004 (2012).
63. De La Serna IL, Ohkawa Y, Higashi C et al. The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocyte-specific genes. J. Biol. Chem. 281(29), 20233-20241 (2006).
64. Keenen B, Qi H, Saladi SV, Yeung M, De La Serna IL. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. Oncogene 29(1), 81-92 (2010).
65. Vachtenheim J, Ondrusova L, Borovansky J. SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells. Biochem. Biophys. Res. Commun. 392(3), 454-459 (2010).
66. Bentley NJ, Eisen T, Goding CR. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol. 14(12), 7996-8006 (1994).
67. Yavuzer U, Keenan E, Lowings P, Vachtenheim J, Currie G, Goding CR. The Microphthalmia gene product interacts with the retinoblastoma protein in vitro and is a target for deregulation of melanocyte-specific transcription. Oncogene 10(1), 123-134 (1995).
68. Carreira S, Goodall J, Aksan I et al. MITF cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433(7027), 764-769 (2005).
69. Loercher AE, Tank EM, Delston RB, Harbour JW. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168(1), 35-40 (2005).
70. Du J, Widlund HR, Horstmann MA et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6(6), 565-576 (2004).
71. Busca R, Berra E, Gaggioli C et al. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J. Cell Biol. 170(1), 49-59 (2005).
72. Mcgill GG, Horstmann M, Widlund HR et al. Bcl2 regulation by the melanocyte master regulator MITF modulates lineage survival and melanoma cell viability. Cell 109(6), 707-718 (2002).
73. Carreira S, Liu B, Goding CR. The gene encoding the Tbox factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J. Biol. Chem. 275(29), 21920-21927 (2000).
74. Bejar J, Hong Y, Schartl M. MITF expression is sufficient to direct differentiation of medaka blastula derived stem cells to melanocytes. Development 130(26), 6545-6553 (2003).
75. Jacobs JJ, Keblusek P, Robanus-Maandag E et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 26(3), 291-299 (2000).
76. Prince S, Carreira S, Vance KW, Abrahams A, Goding CR. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res. 64(5), 1669-1674. (2004).
77. Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 65(6), 2260-2268 (2005).
78. Carreira S, Goodall J, Denat L et al. MITF regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20(24), 3426-3439 (2006).
79. Ohanna M, Giuliano S, Bonet C et al. Senescent cells develop a PARP1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 25(12), 1245-1261 (2011).
80. Bentley DJ, Harrison C, Ketchen AM et al. DNA ligase I null mouse cells show normal DNA repair activity but altered DNA replication and reduced genome stability. J. Cell Sci. 115(Pt 7), 1551-1561 (2002).
81. Tomkinson AE, Mackey ZB. Structure and function of mammalian DNA ligases. Mutat. Res. 407(1), 1-9 (1998).
82. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet. 8(10), 735-748 (2007).
83. Artandi SE, Depinho RA. Mice without telomerase: what can they teach us about human cancer? Nat. Med. 6(8), 852-855 (2000).
84. Artandi SE, Depinho RA. Telomeres and telomerase in cancer. Carcinogenesis 31(1), 9-18 (2010).
85. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193), 2011-2015 (1994).
86. Rudolph KL, Chang S, Lee HW et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96(5), 701-712 (1999).
87. Ouhtit A, Gaur RL, Abd Elmageed ZY et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim. Biophys. Acta 1795(2), 130-136 (2009).
88. Fagiani E, Giardina G, Luzi L et al. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas. Cancer Res. 67(7), 3064-3073 (2007).
89. Murakami H, Arnheiter H. Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner. Pigment Cell Res. 18(4), 265-277 (2005).
90. Bertolotto C, Lesueur F, Giuliano S et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375), 94-98 (2011).
91. Yokoyama S, Woods SL, Boyle GM et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375), 99-103 (2011).
92. Li J, Song JS, Bell RJ et al. YY1 regulates melanocyte development and function by cooperating with MITF. PLoS Genet. 8(5), e1002688 (2012).